Apatinib + Ifosfamide and Etoposide for Relapsed or Refractory Osteosarcoma

NCT04690231 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

79

Enrollment

OTHER

Sponsor class

Conditions

Effect of Drug
Toxicity, Drug
Secondary Resistance

Interventions

DRUG: Apatinib Mesylate
DRUG: ifosfamide and etoposide

Sponsor

Peking University People's Hospital

Collaborators

[object Object]